ロード中...
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes,...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Rockefeller University Press
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3328367/ https://ncbi.nlm.nih.gov/pubmed/22430491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111512 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|